Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors
The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
1. A method of treating a subject with a therapeutic agent that treats or inhibits type 2 diabetes, wherein the subject is suffering from type 2 diabetes, the method comprising the steps of:
determining whether the subject has an Inhibin Subunit Beta E (INHBE) variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide by:
obtaining or having obtained a biological sample from the subject; and
performing or having performed a genotyping assay on the biological sample to determine if the subject has a genotype comprising the INHBE variant nucleic acid molecule; and
when the subject is INHBE reference, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits type 2 diabetes in a standard dosage amount, and/or administering to the subject an INHBE inhibitor; and
when the subject is heterozygous for an INHBE variant nucleic acid molecule, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits type 2 diabetes in an amount that is the same as or lower than a standard dosage amount, and/or administering to the subject an INHBE inhibitor;
when the subject is homozygous for an INHBE variant nucleic acid molecule, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits type 2 diabetes in an amount that is the same as or lower than a standard dosage amount;
wherein the presence of a genotype having the INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide indicates the subject has a decreased risk of developing type 2 diabetes.
2. The method according to claim 1 , wherein the subject is INHBE reference, and the subject is administered or continued to be administered the therapeutic agent that treats or inhibits type 2 diabetes in a standard dosage amount, and/or is administered an INHBE inhibitor.
3. The method according to claim 1 , wherein the subject is heterozygous for an INHBE variant nucleic acid molecule, and the subject is administered or continued to be administered the therapeutic agent that treats or inhibits type 2 diabetes in an amount that is the same as or lower than a standard dosage amount, and/or is administered an INHBE inhibitor.
4. The method according to claim 1 , wherein the INHBE variant nucleic acid molecule is a missense variant, a splice-site variant, a stop-gain variant, a start-loss variant, a stop-loss variant, a frameshift variant, or an in-frame indel variant, or a variant that encodes a truncated INHBE polypeptide.
5. The method according to claim 1 , wherein the INHBE inhibitor comprises an antisense nucleic acid molecule that hybridizes to an INHBE mRNA.
6. The method according to claim 1 , wherein the INHBE inhibitor comprises an siRNA that hybridizes to an INHBE mRNA.
7. The method according to claim 1 , wherein the INHBE inhibitor comprises an shRNA that hybridizes to an INHBE mRNA.
8. The method according to claim 1 , wherein the therapeutic agent is chosen from metformin, insulin, glyburide, glipizide, glimepiride, repaglinide, nateglinide, thiazolidinediones, rosiglitazone, pioglitazone, sitagliptin, saxagliptin, linagliptin, exenatide, liraglutide, semaglutide, canagliflozin, dapagliflozin, and empagliflozin, or any combination thereof.
9. A method of treating a subject with a therapeutic agent that treats or inhibits liver inflammation, wherein the subject is suffering from liver inflammation, the method comprising the steps of:
determining whether the subject has an Inhibin Subunit Beta E (INHBE) variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide by:
obtaining or having obtained a biological sample from the subject; and
performing or having performed a genotyping assay on the biological sample to determine if the subject has a genotype comprising the INHBE variant nucleic acid molecule; and
when the subject is INHBE reference, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits liver inflammation in a standard dosage amount, and/or administering to the subject an INHBE inhibitor; and
when the subject is heterozygous for an INHBE variant nucleic acid molecule, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits liver inflammation in an amount that is the same as or lower than a standard dosage amount, and/or administering to the subject an INHBE inhibitor;
when the subject is homozygous for an INHBE variant nucleic acid molecule, then administering or continuing to administer to the subject the therapeutic agent that treats or inhibits liver inflammation in an amount that is the same as or lower than a standard dosage amount;
wherein the presence of a genotype having the INHBE variant nucleic acid molecule encoding an INHBE predicted loss-of-function polypeptide indicates the subject has a decreased risk of developing liver inflammation.
10. The method according to claim 9 , wherein the subject is INHBE reference, and the subject is administered or continued to be administered the therapeutic agent that treats or inhibits liver inflammation in a standard dosage amount, and/or is administered an INHBE inhibitor.
11. The method according to claim 9 , wherein the subject is heterozygous for an INHBE variant nucleic acid molecule, and the subject is administered or continued to be administered the therapeutic agent that treats or inhibits liver inflammation in an amount that is the same as or lower than a standard dosage amount, and/or is administered an INHBE inhibitor.
12. The method according to claim 9 , wherein the INHBE variant nucleic acid molecule is a missense variant, a splice-site variant, a stop-gain variant, a start-loss variant, a stop-loss variant, a frameshift variant, or an in-frame indel variant, or a variant that encodes a truncated INHBE polypeptide.
13. The method according to claim 9 , wherein the INHBE inhibitor comprises an antisense nucleic acid molecule that hybridizes to an INHBE mRNA.
14. The method according to claim 9 , wherein the INHBE inhibitor comprises an siRNA that hybridizes to an INHBE mRNA.
15. The method according to claim 9 , wherein the INHBE inhibitor comprises an shRNA that hybridizes to an INHBE mRNA.
16. The method according to claim 9 , wherein the therapeutic agent is a hepatitis therapeutic or a hepatitis vaccine.